Primary study · included by 1 review

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis

Matsuda 2015 · Matsuda Chu, Munemoto Yoshinori, Mishima Hideyuki, et al. · Cancer Chemotherapy and Pharmacology · 2015

Included by

Non-Cochrane · intervention · 2026 · cited as Matsuda 2015 · Table 1

Outcome this study informs	Pooled effect	Evidence	Certainty
Chemotherapy-induced oral mucositis (grade 2 or higher by CTCAE v5.0, described as more than grade 1) Hangeshashinto (TJ-14) during chemotherapy vs No hangeshashinto or placebo	RR 0.86 [0.73, 1.00]	6 studies · 293 participants	Moderate
Chemotherapy-induced oral mucositis (grade 2 or higher by CTCAE v5.0, described as more than grade 1) Hangeshashinto (TJ-14) during chemotherapy vs No hangeshashinto or placebo	RR 0.90 [0.67, 1.21]	4 studies	GRADE not reported
Chemotherapy-induced oral mucositis (grade 2 or higher by CTCAE v5.0, described as more than grade 1) Hangeshashinto (TJ-14) during chemotherapy vs No hangeshashinto or placebo	RR 0.81 [0.56, 1.17]	2 studies	GRADE not reported

1 including review in total.